GLPwatch
Papers (10404)
Page 76 of 174, ranked by citation count.
- Acute effects of glucagon-like peptide-1, GLP-1<sub>9-36 amide</sub>, and exenatide on mesenteric blood flow, cardiovascular parameters, and biomarkers in healthy volunteers.
- Efficacy of different antidiabetic drugs based on metformin in the treatment of type 2 diabetes mellitus: A network meta-analysis involving eight eligible randomized-controlled trials.
- Exenatide induces autophagy and prevents the cell regrowth in HepG2 cells.
- [<sup>68</sup>Ga]Ga-NOTA-MAL-Cys<sup>39</sup>-exendin-4, a potential GLP-1R targeted PET tracer for the detection of insulinoma.
- Efficacy and safety of once-weekly glucagon-like peptide-1 receptor agonists compared with exenatide and liraglutide in type 2 diabetes: a systemic review of randomised controlled trials.
- Safety and efficacy of liraglutide on reducing visceral and ectopic fat in adults with or without type 2 diabetes mellitus: A systematic review and meta-analysis.
- Semaglutide Modulates Extracellular Matrix Production of LX-2 Cells via Exosomes and Improves Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
- Utilization of Anti-obesity Medications After Bariatric Surgery: Analysis of a Large National Database.
- Liraglutide pharmacokinetics and exposure-response in adolescents with obesity.
- Effects of combined metformin and semaglutide therapy on body weight, metabolic parameters, and reproductive outcomes in overweight/obese women with polycystic ovary syndrome: a prospective, randomized, controlled, open-label clinical trial.
- Novel double-layered PLGA microparticles-dissolving microneedle (MPs-DMN) system for peptide drugs sustained release by transdermal delivery.
- Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system.
- Improvement in glycaemic parameters using SGLT-2 inhibitor and GLP-1 agonist in combination in an adolescent with diabetes mellitus and Prader-Willi syndrome: a case report.
- Exendin-4 promotes pancreatic β-cell proliferation via inhibiting the expression of Wnt5a.
- Functional association of the N-terminal residues with the central region in glucagon-related peptides.
- The cardioprotective effect of human glucagon-like peptide-1 receptor agonist (semaglutide) on cisplatin-induced cardiotoxicity in rats: Targeting mitochondrial functions, dynamics, biogenesis, and redox status pathways.
- Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective.
- Lixisenatide Reduced Damage in Hippocampus CA1 Neurons in a Rat Model of Cerebral Ischemia-Reperfusion Possibly Via the ERK/P38 Signaling Pathway.
- Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3.
- Lixisenatide treatment for older patients with type 2 diabetes mellitus uncontrolled on oral antidiabetics: meta-analysis of five randomized controlled trials.
- Mechanism of Semaglutide in MASLD Treatment: Where Is the Master Key?
- LIRAGLUTIDE ALLEVIATES ACUTE LUNG INJURY AND MORTALITY IN PNEUMONIA-INDUCED SEPSIS THROUGH REGULATING SURFACTANT PROTEIN EXPRESSION AND SECRETION.
- Heterologous Expression and Delivery of Biologically Active Exendin-4 by Lactobacillus paracasei L14.
- Anterior ischemic optic neuropathy in patients treated with semaglutide: report of four cases with a possible association.
- GLP-1 and the Degenerating Brain: Exploring Mechanistic Insights and Therapeutic Potential.
- Effect of bariatric surgery combined with medical therapy versus intensive medical therapy or calorie restriction and weight loss on glycemic control in Zucker diabetic fatty rats.
- Chronic exendin-4 treatment prevents the development of cancer cachexia symptoms in male rats bearing the Yoshida sarcoma.
- Exenatide reverses dysregulated microRNAs in high-fat diet-induced obese mice.
- Microvascular Density and Circulating Endothelial Progenitor Cells Before and After Treatment with Incretin Mimetics in Diabetic Patients.
- Dulaglutide as an Add-on to Insulin in Type 2 Diabetes; Clinical Efficacy and Parameters Affecting the Response in Real-World Practice.
- Dulaglutide-related bullous pemphigoid in a patient with type 2 diabetes: A case report.
- Similar weight loss with semaglutide regardless of diabetes and cardiometabolic risk parameters in individuals with metabolic dysfunction-associated steatotic liver disease: Post hoc analysis of three randomised controlled trials.
- The Use of Semaglutide in Patients With Renal Failure-A Retrospective Cohort Study.
- Optimization of Enzymolysis Clearance Strategy To Enhance Renal Clearance of Radioligands.
- Semaglutide promotes the transition of microglia from M1 to M2 type to reduce brain inflammation in APP/PS1/tau mice.
- Nonclinical safety and pharmacokinetics of Miglyol 812: A medium chain triglyceride in exenatide once weekly suspension.
- Semaglutide effects on energy balance are mediated by Adcyap1<sup>+</sup> neurons in the dorsal vagal complex.
- Differential effects of intra-ventral tegmental area ghrelin and glucagon-like peptide-1 on the stimulatory action of D-amphetamine and cocaine-induced ethanol intake in male Sprague Dawley rats.
- Efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: PIONEER 12, a double-blind, Phase IIIa, randomised trial.
- Tirzepatide and potential use for metabolically healthy obesity.
- Microneedle patch with pure drug tips for delivery of liraglutide: pharmacokinetics in rats and minipigs.
- Liraglutide does not change bone turnover in clozapine- and olanzapine-treated schizophrenia overweight patients with prediabetes - randomized controlled trial.
- Treatment of insulin resistance with tirzepatide leading to improvement of hair loss.
- Pharmacological Treatment of Obesity in Older Adults.
- A GLP1R gene variant and sex influence the response to semaglutide treatment in patients with severe obesity.
- Glucagon-like peptide-1 receptor expression after myocardial infarction: Imaging study using <sup>68</sup>Ga-NODAGA-exendin-4 positron emission tomography.
- 10-fold liraglutide overdose over 7 months resulted only in minor side-effects.
- LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial.
- Protective effect of the glucagon-like peptide-1 analogue liraglutide on carbon tetrachloride-induced acute liver injury in mice.
- Kidney Parameters with Tirzepatide in Obesity with or without Type 2 Diabetes.
- Drug Delivery Strategies for Enhancing the Therapeutic Efficacy of Toxin-Derived Anti-Diabetic Peptides.
- Real-world use and effectiveness of tirzepatide among people without evidence of type 2 diabetes in the United States.
- Early use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in type 2 diabetes.
- Semaglutide combined with empagliflozin vs. monotherapy for non-alcoholic fatty liver disease in type 2 diabetes: Study protocol for a randomized clinical trial.
- Exendin-4 Improves Diabetic Kidney Disease in C57BL/6 Mice Independent of Brown Adipose Tissue Activation.
- Plasma proteomics reveals an improved cardio-metabolic profile in patients with type 2 diabetes post-liraglutide treatment.
- Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis.
- Current Insights, Advantages and Challenges of Small Molecule Glucagon-like Peptide 1 Receptor Agonists: A Scoping Review.
- Pharmacotherapy for obesity in individuals with type 2 diabetes.
- Tirzepatide and health-related quality of life in adults with obesity or overweight: Results from the SURMOUNT-3 phase 3 randomized trial.